<DOC>
	<DOCNO>NCT01472809</DOCNO>
	<brief_summary>The purpose study determine ( 1 ) whether ZYGK1 safe well tolerate , ( 2 ) pharmacokinetics ( body ZYGK1 ) ( 3 ) pharmacodynamics ( drug body ) healthy diabetic subject .</brief_summary>
	<brief_title>A Clinical Study Evaluate Safety , Tolerability Pharmacokinetics Oral ZYGK1 Healthy Volunteers</brief_title>
	<detailed_description>This study randomize , double blind , placebo control study divide four plan : 1 . Plan I : Single Ascending Dose ( SAD ) Study 2 . Plan II : Multiple Ascending Dose ( MAD ) Study 3 . Plan III : Gender Effect study 4 . Plan IV : Food Effect study First Plan I , Plan III Plan IV conduct healthy volunteer . After review result , decision shall take whether multiple ascend dos shall study healthy human volunteer subject type 2 diabetes .</detailed_description>
	<criteria>1 . Age : 1845 year 2 . Mentally , physically , legally eligible give inform consent 3 . Male female volunteer weigh 5075 kg 4575 kg ( 4 ) respectively . 4 . Ability communicate effectively study personnel 5 . Willingness adhere protocol requirement 6 . For gender effect study , females history sterility least one year menopause use long acting nonhormonal contraceptive measure ( e.g. , intrauterine device ) recruit . 7 . At least one panel , single ascend dose multiple ascend dose include subject type 2 diabetes define American Diabetes Association 1 . Presence history hypersensitivity active inactive ingredient ZYGK1 formulation 2 . Presence history pancreatitis time ( Serum Amylase/Serum Lipase upper normal limit ( UNL ) ) 3 . Presence history severe gastrointestinal disease last 6 month 4 . Presence history renal insufficiency time ( serum creatinine &gt; UNL ) 5 . Active liver disease and/or liver transaminases great 1.5 X UNL 6 . History presence systemic disorder disease ( e.g. , respiratory , gastrointestinal , endocrine , immunological , dermatological , neurological , psychiatric disease body system involvement ) 7 . Abnormal bleeding time ( BT ) , clot time ( CT ) , prothrombin time ( PT ) , activate partial prothrombin time ( APTT ) 8 . History presence medication last 14 day 9 . History presence significant alcoholism drug abuse within past 1 year 10 . History presence significant smoking ( 10 cigarette per day ) consumption tobacco product ( 10 time per day ) 11 . Difficulty donate blood 12 . Systolic blood pressure 140 mmHg less 100 mmHg diastolic blood pressure 90 mmHg less 60 mmHg 13 . Pulse rate le 60 minute 100/minute 14 . Any clinically significant laboratory finding screen 15 . History presence clinically significant electrocardiogram ( ECG ) abnormalities screen 16 . Major illness and/or major surgery last 3 month 17 . Volunteers participate drug research study present trial within past 3 month 18 . Volunteers donate one unit ( 350 ml ) blood past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>ZYGK1</keyword>
	<keyword>Cadila</keyword>
	<keyword>Zydus</keyword>
	<keyword>ZRC</keyword>
	<keyword>Zydus Research Center</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Diabetes</keyword>
</DOC>